MOTS-c Safety Signals & FDA Actions: What the Current Evidence Shows

HealthRX.com

FDA has no human safety data on MOTS-c so far

Print or save as PDF

See the public record for MOTS-c

  • FDA approval / None, for any indication [1]
  • FDA compounding lists / Absent from the pharmacy and outsourcing-facility lists [5][6][7]
  • Advisory committee vote / In favor of listing, July 23, 2026, non-binding [2][3]
  • HHS policy / Draft enforcement discretion filed October 28, 2026 [3][4]
  • Sport / Prohibited at all times by WADA [8][9]
  • Main stated risk / Immunogenicity from aggregation and peptide impurities [10]
  • Molecular size / 16 amino acids, about 2174.6 g/mol [1]

What MOTS-c is and what has actually been tested

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide with a molecular weight of about 2174.6 g/mol, encoded in mitochondrial DNA and first reported in 2015 by Lee and colleagues in Cell Metabolism [1][11].

In mice, MOTS-c treatment prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity. Skeletal muscle appeared to be the primary target organ, and its cellular actions inhibit the folate cycle and its tethered de novo purine biosynthesis, leading to AMPK activation [11]. Injected MOTS-c also improved physical performance in young, middle-aged and old mice, and late-life intermittent treatment increased physical capacity and healthspan in mice [12].

FDA noted that the molecular targets are unknown and that no dose-response relationships were assessed [1].

Do any human studies exist?

Human studies exist, but they measure the body's own MOTS-c. In a randomized trial, 30 healthy adults were assigned to endurance exercise (n=10), resistance exercise (n=10) or control (n=10). Circulating humanin rose after endurance exercise, MOTS-c showed only a trend to increase, and plasma MOTS-c was not related to fitness [13]. In a separate study, exercise induced endogenous MOTS-c expression in human skeletal muscle and in circulation [12]. Participants in these studies exercised; none was given the peptide [12][13].

FDA's July 2026 evaluation searched PubMed, Embase, the Cochrane library and other sources for a study in which MOTS-c was given to a human and found none. The 12 papers the nominator cited were not clinical studies, and the FAERS adverse-event search through March 9, 2025 retrieved no MOTS-c reports [1]. FDA also found that no outsourcing facility reported compounding MOTS-c from January 2017 to December 2025 [1].

FDA's stated safety concerns

The concerns FDA has put in writing are specific:

  • No human exposure data on drug products containing MOTS-c administered by any route [10].
  • The substance is not well characterized: naming is inconsistent, and there are no impurity, aggregate or endotoxin data [1].
  • No human safety or effectiveness data and no animal toxicity studies [1].
  • Injectable peptides may pose an immunogenicity risk from aggregation and peptide-related impurities; MOTS-c has 16 amino acids and no immunogenicity data exist [1][10].
  • FDA-approved treatments already exist for obesity and osteoporosis, two of the nominated uses [1].

What people on Reddit report

Reddit posts and replies about FDA's safety reviews of peptides, including MOTS-c, and how compounded product quality is checked. Accounts range from summaries of reviewer concerns to distrust of FDA's priorities.

ps4roompromdfriends4 · Biohackers

Most of them aren't well characterized chemically(purity, stability, impurities, or how they tend to clump together). They highlighted a real risk of immune reactions, especially with injectables or nasal forms when compounded, plus general worries about quality control and formulation in a pharmacy setting.

The poster summarizes reviewer worries about unclear chemistry, immune reactions from injectables, and quality control at pharmacies.

Read the source discussion

ksunderlal · bpc_157

FDA is less concerned about potential benefits and more about safety. In the case of these meetings they were overruled by the advisory committee who felt that not permitting access had more downside risk than regulating an approved compounding pharmacy process.

The commenter says FDA weighs safety over benefit and that an advisory committee overruled staff on access.

Read the source discussion

Questions worth asking

Choose the questions you want to keep

What FDA has done, in order

FDA's page on bulk substances that may raise significant safety risks, content dated April 22, 2026, lists MOTS-c in the 'nominated but withdrawn' table, which holds substances previously in category 2 whose nominators withdrew them. Removal from category 2 was not a finding that MOTS-c is safe [10].

MOTS-c appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026) and is absent from FDA's list for outsourcing facilities (updated March 21, 2025) [5][6][7]. FDA's category 1 policy, under which the agency generally does not act against compounders who meet the stated conditions, does not cover it [5][6][7].

In a July 2026 briefing document, FDA staff proposed that neither the free base nor the acetate salt be added to the pharmacy bulks list [1]. The reasons given were that the substance is not well characterized and its use in compounding is unknown. There are also no human safety or effectiveness data and no animal toxicity studies, and approved treatments exist for two of the nominated uses [1]. The nominated uses were insulin resistance, obesity, osteoporosis, vascular calcification, muscle and fat metabolism, and longevity, as 5 mg and 10 mg subcutaneous injections [1].

The Pharmacy Compounding Advisory Committee reviewed MOTS-c on July 23, 2026 and voted in favor of adding it to the bulks list, against the staff recommendation [2][3]. Advisory committee recommendations are advice only and are not binding on FDA, and adding a substance to the list requires formal rulemaking; MOTS-c is not on the list [2][3].

On October 28, 2026, HHS filed a draft enforcement-discretion policy covering six peptides: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. Federal Register publication is scheduled for October 30, 2026, with comments due two weeks after publication [3][4]. For MOTS-c acetate given by subcutaneous or intramuscular injection, HHS says it 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician that meets the policy's conditions. These conditions include a single active ingredient, a patient-specific prescription, a manufacturer registered with FDA that supplies a certificate of analysis, and a label reading 'This is a compounded drug product. Not for resale.' [3][4].

The same notice states that it 'does not establish any rights for any person and is not binding on HHS or the public,' and that HHS may revisit it if a safety signal or product quality issue arises. It also states that compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before marketing [3].

Does the advisory vote or the HHS draft make MOTS-c approved?

No. The advisory vote is not a listing, and the HHS document is a draft, non-binding statement covering the acetate form by injection [2][3]. MOTS-c remains unapproved and is not a component of an approved drug. It has no USP or National Formulary monograph, no listing in the European or Japanese pharmacopeias, and no product authorized by the European Medicines Agency [1].

Is MOTS-c banned in sport?

WADA names it explicitly in S4.4.1 among metabolic modulators (activators of AMP-activated protein kinase) and prohibits it at all times, in and out of competition [8]. S4.4 substances are non-Specified Substances [8]. It is on the 2026 Prohibited List, in force since January 1, 2026, and remains on the 2027 tracked-changes version dated August 26, 2026 [8][9]. FDA notes it was already on the 2024 List [1].

What about dose and pharmacokinetics?

There is no approved dose. The nominated products were 5 mg and 10 mg subcutaneous injections, which are what FDA evaluated, not a recommended dose. The rodent doses studied, 0.5 to 15 mg/kg, cannot be converted into human doses [1].

FDA found no pharmacokinetic data for MOTS-c in humans or in live animals [1]. The only kinetic observation in the record is an in-vitro study in which MOTS-c is quickly broken down in human blood, which raises the question of whether an injection can produce active levels in people [1].

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. What did the Pharmacy Compounding Advisory Committee vote to do about MOTS-c on July 23, 2026?

Question 1 of 4

Score: 0 right, 0 of 4 answered

Is MOTS-c FDA approved?
No. MOTS-c is not an FDA-approved drug and is not a component of one. FDA found no USP or National Formulary monograph, no listing in the European or Japanese pharmacopeias, and no product authorized by the European Medicines Agency [1].
What is the main safety concern FDA has stated for MOTS-c?
Immunogenicity, meaning an immune reaction to the injected peptide, from aggregation and peptide-related impurities, together with the absence of human exposure data, animal toxicity studies and impurity or endotoxin data [1][10].
Did the FDA advisory committee vote to allow MOTS-c compounding?
The Pharmacy Compounding Advisory Committee voted in favor of adding MOTS-c to the bulk substances list on July 23, 2026, against FDA staff recommendation [2][3]. The vote is non-binding advice and MOTS-c is not on the list; adding it requires formal rulemaking [2][3].
Does the October 2026 HHS policy make MOTS-c legal?
No. It is a draft policy saying HHS does not intend to take enforcement action against certain pharmacies and physicians compounding MOTS-c acetate for injection if its conditions are met [3][4]. The notice says it is not binding on HHS or the public and establishes no rights for anyone [3].
Is MOTS-c on FDA's compounding lists?
No. It appears in none of FDA's three categories for state-licensed pharmacies and physicians and is absent from FDA's outsourcing-facility list [5][6][7]. FDA's page on substances that may raise significant safety risks lists it in the 'nominated but withdrawn' table, and removal from category 2 was not a finding that it is safe [10].
Is MOTS-c prohibited in sport?
Yes. WADA names MOTS-c in S4.4.1 as an AMPK activator and prohibits it at all times, in and out of competition, both on the 2026 List and the 2027 tracked-changes version [8][9].
Show all 15 referencesHide references
  1. U.S. Food and Drug Administration.
  2. U.S. Food and Drug Administration.
  3. Official web page.
  4. Official web page.
  5. U.S. Food and Drug Administration.
  6. U.S. Food and Drug Administration.
  7. Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
  8. World Anti-Doping Agency.
  9. World Anti-Doping Agency.
  10. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  11. Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54.
  12. Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470.
  13. von Walden F, Fernandez-Gonzalo R, Norrbom J, Emanuelsson EB, Figueiredo VC, Gidlund EK, et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. J Appl Physiol (1985). 2021;131(3):1035-1042.
  14. Reddit participants. With RFK Jr. advocating greater access to trendy peptides via compounding, FDA scientists highlight insufficient human evidence and safety r (r/Biohackers). Accessed 2026-11-10.
  15. Reddit participants. Where BPC-157 and TB-500 stand with FDA after the July committee votes (r/bpc_157). Accessed 2026-11-10.
Evidence overview for MOTS-c Safety Signals & FDA Actions: What the Current Evidence Shows